Boehringer Ingelheim completes IPF/PPF antifibrotic survey; BI 3822971 trial still recruiting
A real-world survey on antifibrotic therapy experiences in Japan has completed, while the Phase I BI 3822971 solid tumor trial continues recruiting at select sites.
Boehringer Ingelheim had one trial update and one ongoing early-stage oncology study this week.
- "A Real-World Study of the Perceived Emotional and Social Experiences Related to Antifibrotic Therapy in Patients With IPF and PPF: A Cross-Sectional Web-Based Survey" (NCT07743996) has completed. The cross-sectional study was conducted across Japan using an online patient-reported outcome questionnaire1, examining patients' attitudes and experiences regarding the emotional and social impact of side effects from antifibrotic treatment among Japanese patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis, and how these attitudes relate to individual patient characteristics1. Enrollment reached 122 participants (actual)1, with both start and completion dates listed as 2026-08-01 and 2026-09-30, respectively1.
- "A First-in-human, Open-label, Phase I Trial to Determine the Safety and Tolerability of BI 3822971 in Patients With Unresectable Advanced or Metastatic Solid Cancers" (NCT07744152) remains recruiting. The study is testing BI 3822971, which is being developed to help the immune system fight cancer2, in an estimated 137 participants2 with advanced solid tumors. Of the sites across Belgium, China, Germany, the Netherlands and Spain, only four in Spain are listed as recruiting, with the rest "not yet recruiting."2
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.